Julie Rubinstein Sells 30,941 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the firm’s stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $14.66, for a total value of $453,595.06. Following the completion of the sale, the chief operating officer directly owned 395,146 shares of the company’s stock, valued at $5,792,840.36. This trade represents a 7.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.55, for a total value of $277,323.00.
• On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.18, for a total value of $270,270.80.
• On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total value of $250,639.00.
• On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.77, for a total value of $243,396.20.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.56, for a total value of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total value of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total value of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total value of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total value of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total value of $251,210.80.

Adaptive Biotechnologies Stock Down 0.1%

ADPT stock opened at $14.20 on Thursday. Adaptive Biotechnologies Corporation has a twelve month low of $7.16 and a twelve month high of $20.76. The stock’s 50 day moving average is $14.58 and its 200-day moving average is $15.99. The firm has a market capitalization of $2.19 billion, a PE ratio of -35.50 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same quarter last year, the company earned ($0.23) earnings per share. The company’s revenue for the quarter was up 51.0% on a year-over-year basis. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ADPT shares. Guggenheim boosted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently bought and sold shares of the business. Allianz Asset Management GmbH lifted its holdings in Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after acquiring an additional 242,474 shares during the period. SG Americas Securities LLC raised its stake in shares of Adaptive Biotechnologies by 82.5% in the third quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock valued at $1,019,000 after buying an additional 30,785 shares during the period. Affinity Wealth Management LLC bought a new stake in shares of Adaptive Biotechnologies in the third quarter valued at $4,541,000. Lisanti Capital Growth LLC bought a new stake in shares of Adaptive Biotechnologies in the third quarter valued at $4,476,000. Finally, Aristotle Atlantic Partners LLC raised its stake in shares of Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock valued at $46,776,000 after buying an additional 247,402 shares during the period. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.